The domain of pet tumors has garnered substantial focus in recent times. With the progression of our comprehension of cancer biology and diagnostic methodologies, a pronounced need has arisen for dependable and sophisticated oncology diagnostics tailored for pets. BioVenic is a leading biotechnology and diagnostics company dedicated to providing customers with innovative and effective in vitro diagnostic development solutions for pet oncology.
Fig 1. Canine tumor biomarkers and their role in diagnosis.1
Pet Oncology Diagnostics Development Services
The same as humans, pets can also get cancer, such as osteosarcoma, lymphoma, breast cancer, and melanoma. The prevalence of cancer in pets has been increasing, highlighting the need for effective tools to aid in early diagnosis. BioVenic helps design a range of innovative solutions to improve cancer diagnosis research and development for companion animals.
Genetic Counseling and Risk Assessment
Our genetic counselors provide comprehensive information about genetic alterations, hereditary cancer risks, and potential implications for the pet's health. By assessing the pet's genetic background, family history, and breed predispositions, we offer personalized risk assessment and guidance on preventive measures or screening protocols for high-risk pets.
Comparative Oncology Research
BioVenic actively engages in comparative oncology research, collaborating with leading academic institutions. Through translational research, we help clients investigate shared molecular mechanisms, therapeutic targets, and biomarkers between human and pet cancers. Our goal is to help animal health researchers accelerate advances in pet cancer diagnostics research.
Common Pet Tumors
We offer diagnostics development solutions for a wide range of pet tumors, including but not limited to the common pet tumors listed in the table below.▼
|
Skin cancer
|
Intestinal cancer
|
Connective tissue cancer (sarcomas)
|
|
Bladder cancer
|
Nose cancer/nasal tumors
|
Soft tissue sarcoma
|
|
Breast (mammary) cancer
|
Mouth (oral) cancer
|
Lymphatic tissue cancer (lymphoma)
|
|
Bone cancer (osteosarcoma)
|
Stomach cancer
|
Mammary tumor
|
|
Leukemia
|
Hemangiosarcoma
|
Brain tumor
|
|
Lymphosarcoma
|
Transmissible venereal tumor
|
Mast cell tumor
|
|
Endocrine tumor
|
Plasmacytoma
|
Mammary cancer
|
|
Osteosarcoma
|
Melanoma
|
Pancreatic tumor
|
Common Pet Tumors Biomarkers
Understanding the molecular characteristics of common pet tumors is essential for accurate diagnosis decision-making. by BioVenic help develop diagnostic assays for a variety of tumor-associated biomarkers, including cell surface proteins, enzymes, genes, gene products, hormones, or specific cells, including, but not limited to, those listed in the table.▼
|
EGFR
|
B catenin
|
pSmad2
|
IGFR1
|
PTHR1/PTHrP
|
|
HER2
|
PDGF alpha
|
TAZ/YAP
|
HES1
|
TP53
|
|
Survivin
|
CDKN2A(P16)
|
CD204+ macrophages
|
Ezrin
|
Monocytes
|
|
CD3+
|
miR-233-3p
|
miR-130a-3p
|
let-7b-5p
|
Lymphocytes
|
|
CD8+
|
Treg cells
|
FOXP3+ cells
|
Circulating tumor cells
|
Extracellular vesicles
|
|
Extracellular vesicles
|
miR-23a-3p
|
IL-8
|
miR-214
|
IL-12p40
|
|
miR-126
|
TGFB1
|
cfDNA
|
CTC
|
miR-30c-5p
|
|
EpCAM+
|
CLDN7 gene
|
CK+
|
DAPI+
|
LDH
|
|
CD45- CTCs
|
CRYAB gene
|
CD11b+
|
ATP8B1 gene
|
EGFR gene
|
|
CD5-
|
CD21-
|
MHCII-
|
MDSCs
|
ALP
|
|
HER
|
Ki-67
|
p53
|
BRCA1/2
|
AMH
|
|
TK1
|
miRNA
|
CEA
|
Thyroxine/Thyroglobulin
|
ACTH
|
|
Androstenedione
|
Insulin
|
17-hydroxyprogesterone
|
PAP
|
Estradiol
|
|
CA-125
|
PSA
|
Fibronectin
|
Sialic Acid
|
APP
|
|
Cardiac troponin I
|
cLBT
|
ALK gene
|
ROS1 gene
|
c-MET gene
|
|
HER2 gene
|
FOB
|
TP5
|
BRCA2
|
ATM
|
Tumor Biomarkers Discovery Platform
Our platform combines state-of-the-art technologies, extensive bioinformatics analysis, and a multidisciplinary approach to uncover promising biomarkers that can revolutionize the field of pet oncology.
High-Throughput Screening
By employing techniques such as gene expression profiling, proteomics, metabolomics, and epigenetics, we help clients comprehensively assess the molecular landscape of tumors and identify biomarker candidates with significant diagnostic potential.
Data Integration and Analysis
The vast amount of data generated from our high-throughput screening is processed and integrated using sophisticated bioinformatics tools and algorithms. This allows us to identify potential molecular signatures associated with specific tumor types.
Machine Learning
BioVenic employs advanced machine learning techniques to extract valuable insights from integrated data sets. The platform can predict tumor biomarkers based on training algorithms on large data repositories.
Validation Studies
Once potential tumor markers are identified through our platform, we help clients conduct rigorous validation studies. These studies involve a larger cohort of pet patients, encompassing different breeds, ages, and stages of tumor.
Our Service Flowchart
Why Choose Us?
We develop state-of-the-art pet tumor diagnostic methods for our customers based on our extensive expertise, including FISH, NGS, and more.
Our dedicated team of experienced molecular biologists, pathologists, and genetic counselors is committed to providing personalized diagnostic development services.
From comprehensive tumor analysis and biomarker analysis to skilled genetic counseling, BioVenic provides a one-stop pet tumor diagnosis solution.
BioVenic's pet oncology in vitro diagnostics development solutions are designed to provide customers with accurate, reliable, and personalized information for effective cancer management in pets. For any inquiries or further information, we encourage you to contact us.
References
-
Luu, Anita K., et al. Viloria-Petit. "Recent advances in the discovery of biomarkers for canine osteosarcoma." Frontiers in Veterinary Science 8 (2021): 734965.
-
Colombe, Philippe, et al. "Blood biomarkers for canine cancer, from human to veterinary oncology." Veterinary and Comparative Oncology 20.4 (2022): 767-777.
